TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03685032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
Study: NCT02091869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paper Asthma Action Plan
Description: Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Phone
Description: Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
Study: NCT02279147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neostigmine methylsulfate，raceanisodamine hydrochloride
Description: The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
Study: NCT02406885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
Study: NCT04396223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Injection
Description: Avelumab administration at 800mg a 1 hour IV infusion once every 14 days during 4 months ½ (median)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate 1 GM Injection
Description: methotrexate administration at 1mg/kg/day during 4 months ½ (median)
Study: NCT01414413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home assessment and initiation of ART
Description: Home-based ART eligibility assessment (WHO staging, CD4 count measurement and educational treatment preparation) and initiation.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinic-based ART assessment and initiation
Description: Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor.
Study: NCT04238403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (MATCH Protocol)
Description: BPT. Behavioral Parent Training (BPT) is a well-established psychosocial intervention for the treatment for ADHD and related behavioral difficulties (e.g., oppositional problems). BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods (e.g., praise, effective communication, reward systems, time-out from positive reinforcement) to facilitate positive behaviors in their child (e.g., compliance) and reduce challenging behaviors (e.g., opposition). BPT comes in several manualized, commercially available manuals. The version of BPT that we will be utilizing is from the MATCH protocol (Chorpita and Weisz, 2009), which consists of 10 components, delivered with individual families, typically over the course of 10-16 weekly individual meetings (total meetings depends upon parent availability and acquisition of BPT skills).
Study: NCT02393326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial pulpotomy with biodentine
Description: After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Formocresol pulpotomy
Description: Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
Study: NCT03957811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body Vibration exercise
Description: Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
Study: NCT02839564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis
Description: After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Diagnostic laparoscopy
Description: After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
Study: NCT03456999

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MAU868
Description: MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
Study: NCT00971061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed valve implant
Description: 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molteno single-plate implant (MSPI)
Description: 134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
Study: NCT02744482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: risedrante tablet (75 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: risedrante placebo tablet (75 mg)
Study: NCT02079142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Strategy: Train-the-trainer
Description: Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT. Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.~Trainers will then return to Washington University to be trained in how to train their other staff members in IPT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Strategy: Expert Consultation
Description: Investigators will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depression.
Study: NCT00002756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT02339155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVA
Description: Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVA
Description: Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
Study: NCT01180790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
Study: NCT02044341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR01
Description: drops administered an needed for pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycerin ear drops
Description: placebo drops administered for ear pain
Study: NCT03328910

Intervention type: DEVICE
Intervention: SPI monitor (GE Healthcare, Helsinki, Finland)
Description: The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
Study: NCT02183077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam tablet
Study: NCT02339155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Raxibacumab
Description: Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
Study: NCT01393613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Higher dose tablet, once daily, for six weeks,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Middle dose tablet, once daily, for six weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Lower dose tablet, once daily, for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, for six weeks
Study: NCT03321461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMTP1
Description: Fluorescent sites will be removed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICG
Description: Fluorescent sites will be removed
Study: NCT04498416

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative and qualitative assessments of mental health
Description: Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative and qualitative assessments of mental health
Description: Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative and qualitative assessments of mental health
Description: Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale
Study: NCT03919500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO
Description: Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Infants in control group are administered normal saline with the same volume and period as EPO.
Study: NCT02631746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study: NCT04744259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: A psychological intervention which aims to increase activity and reduce depressive symptoms.
Study: NCT04181268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary Intervention
Description: Calcified plaque modification during percutaneous coronary intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary Intervention
Description: Calcified plaque modification during percutaneous coronary intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary Intervention
Description: Calcified plaque modification during percutaneous coronary intervention
Study: NCT02983916

Intervention type: PROCEDURE
Intervention: Adhesiolysis
Description: Diagnostic laparoscopy or laparotomy with lysis of adhesions.
Study: NCT01716923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-303 Red Blood Cells (RBCs) - Test

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, untreated red blood cells (RBCs) - Control
Study: NCT00474383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
Study: NCT02364609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03463538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic capsular release
Description: surgical release of shoulder joint capsule

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydro-dilatation
Description: dilatation of shoulder joint capsule using water pressure under local anesthetic
Study: NCT02791126

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.

Intervention type: OTHER
Intervention: Echocardiogram
Description: For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
Study: NCT02598934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
Study: NCT04136587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonic fluid collection during endoscopy for analysis of the bacterial secretome
Description: Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
Study: NCT01731470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liposomes
Description: Intravesical instillation of liposomes.
Study: NCT00669019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Study: NCT04136587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonic fluid collection during endoscopy for analysis of the bacterial secretome
Description: Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonic fluid collection during endoscopy for analysis of the bacterial secretome
Description: Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonic fluid collection during endoscopy for analysis of the bacterial secretome
Description: Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonic fluid collection during endoscopy for analysis of the bacterial secretome
Description: Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
Study: NCT01974661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COMBIG-DC (ilixadencel)
Description: Allogenic dendrite-cell based therapeutic vaccine
Study: NCT01618071

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat meals varying in their fatty acid composition
Description: 70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat meals varying in their fatty acid composition
Description: 70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-fat meals varying in their fatty acid composition
Description: 70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-fat meals varying in their fatty acid composition
Description: 70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
Study: NCT03799354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal strenght training (MST) plus endurance training (ET)
Description: Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~1. MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~2. ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training (ET)
Description: Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician.
Study: NCT01569750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1, Cohort 1
Description: Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1, Cohort 2
Description: Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1, Cohort 3
Description: Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
Study: NCT02574351

Intervention type: BIOLOGICAL
Intervention: blood draw, breathing test
Description: A blood draw,breathing test will be performed on every participant

Intervention type: BIOLOGICAL
Intervention: blood draw, breathing test
Description: A blood draw,breathing test will be performed on every participant

Intervention type: BIOLOGICAL
Intervention: blood draw, breathing test
Description: A blood draw,breathing test will be performed on every participant

Intervention type: BIOLOGICAL
Intervention: blood draw, breathing test
Description: A blood draw,breathing test will be performed on every participant
Study: NCT02394925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal Test Contact lens
Description: Used in a daily wear modality